

Patent
Attorney Docket No. 033018-121

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Frank E. Blondino et al.

Group Art Unit: 3743

Application No.: 10/734,150

Examiner:

Filing Date: December 15, 2003

Confirmation No.: 2098

Title: AEROSOL FORMULATIONS AND AEROSOL DELIVERY OF BUSPIRONE, BUSPRENORPHINE, TRAIZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM

**FOURTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FOURTH Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By

Peter K. Skiff

Registration No. 31,917


Date: June 14, 2005

BURNS DOANE

BURNS DOANE SWECKER & MATHIS LLP
INTELLECTUAL PROPERTY LAW

**FOURTH
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

(8/04)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Frank E. BLONDINO et al.)	Group Art Unit: 3743
Application No.: 10/734,150)	Examiner:
Filed: December 15, 2003)	Confirmation No.: 2098
For: AEROSOL FORMULATIONS AND)	
AEROSOL DELIVERY OF BUSPIRONE,)	
BUPRENORPHINE, TRIAZOLAM,)	
CYCLOBENZAPRINE AND ZOLPIDEM)	

FOURTH INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit a copy of the International Preliminary Examination Report dated June 7, 2005 for a corresponding application. Pursuant to 37 C.F.R. § 1.98, copies of the documents were previously cited and are not enclosed.

International Preliminary Examination Report for PCT/US03/39819 dated June 7, 2005.

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than 30 (thirty) days prior to the filing of this Information Disclosure Statement.

To assist the Examiner, the document is listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.


Date June 14, 2005

By: 

Peter K. Skiff
Registration No. 31,917

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Substitute for form 1449A/PTO & 1449B/PTO		Complete if Known	
THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/734,150
		Filing Date	December 15, 2003
		First Named Inventor	Frank E. BLONDINO et al.
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	033018-121
Sheet	1	1	



U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation
					Yes No

NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	International Preliminary Examination Report for PCT/US03/39819 dated June 7, 2005

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.